| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Nephrology |
,**
* Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California; Amgen Inc., Thousand Oaks, California; Denver Nephrologists PC, Denver, Colorado; Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; || INSERM Unit 845 and Nephrology, Hopital Necker, Paris, France; ¶ Department of Nephrology, University Hospital, Rheinisch Westfälische Technische Hochschule University of Aachen, Aachen, Germany; ** Division of Nephrology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; Service de Néphrologie Hôpital Manhès, Fleury-Mérogis, France; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; Department of Medicine, Indiana University School of Medicine and Roudebush VAMC, Indianapolis, Indiana; |||| Center for Nephrology, Royal Free and University College Medical School, London, United Kingdom; and ¶¶ Health Sciences Centre, Memorial University of Newfoundland, St. John's, Newfoundland, Canada
Address correspondence to: Dr. Patrick Parfrey, Health Sciences Centre, Memorial University of Newfoundland, St. John's, NL, Canada A1B 3V6. Phone: 709-777-7261; Fax: 709-777-6995; E-mail: pparfrey{at}mun.ca
Background and Objectives: The dramatically high rates of mortality and cardiovascular morbidity observed among dialysis patients highlights the importance of identifying and implementing strategies to lower cardiovascular risk in this population. Results from clinical trials undertaken thus far, including trials on lipid reduction, normalization of hematocrit, and increased dialysis dosage, have been unsuccessful. Available data indicate that abnormalities in calcium and phosphorus metabolism, as a result of either secondary hyperparathyroidism alone or the therapeutic measures used to manage secondary hyperparathyroidism, are associated with an increased risk for death and cardiovascular events. However, no prospective trials have evaluated whether interventions that modify these laboratory parameters result in a reduction in adverse cardiovascular outcomes.
Design, Setting, Participants, & Measurements: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events is a global, phase 3, double-blind, randomized, placebo-controlled trial evaluating the effects of cinacalcet on mortality and cardiovascular events in hemodialysis patients with secondary hyperparathyroidism. Approximately 3800 patients from 22 countries will be randomly assigned to cinacalcet or placebo. Flexible use of traditional therapies will be permitted. The primary end point is the composite of time to all-cause mortality or first nonfatal cardiovascular event (myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular disease, including lower extremity revascularization and nontraumatic amputation).
Results: The study will be event driven (terminated at 1882 events) with an anticipated duration of approximately 4 yr.
Conclusions: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events will determine whether management of secondary hyperparathyroidism with cinacalcet reduces the risk for mortality and cardiovascular events in hemodialysis patients.
This article has been cited by other articles:
|
|
 |
|
  O. Egbuna, S. Quinn, L. Kantham, R. Butters, J. Pang, M. Pollak, D. Goltzman, and E. Brown The full-length calcium-sensing receptor dampens the calcemic response to 1{alpha},25(OH)2 vitamin D3 in vivo independently of parathyroid hormone Am J Physiol Renal Physiol, September 1, 2009; 297(3): F720 - F728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Moe, M. F. Seifert, N. X. Chen, R. M. Sinders, X. Chen, D. Duan, C. Henley, D. Martin, and V. H. Gattone II R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD) Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2371 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Covic, P. Kothawala, M. Bernal, S. Robbins, A. Chalian, and D. Goldsmith Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1506 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. St. Peter, Q. Li, J. Liu, M. Persky, K. Nieman, C. Arko, and G. A. Block Cinacalcet Use Patterns and Effect on Laboratory Values and Other Medications in a Large Dialysis Organization, 2004 through 2006 Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-u. Alam, J. P. Kirton, F. L. Wilkinson, E. Towers, S. Sinha, M. Rouhi, T. N. Vizard, A. P. Sage, D. Martin, D. T. Ward, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells Cardiovasc Res, February 1, 2009; 81(2): 260 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke and E. Ritz Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
